European Society of Cardiology - Welcome

European Society of Cardiology

Welcome to the European Society of Cardiology

Advanced Search | Contact Us | Log in to My ESC

Guidelines & Surveys

Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe

Live from the ESC Congress 2010 in Stockholm

Goodbye and thank you!

The ESC Congress 2010 is now formally over. A very big thank you to all attendees, presenters, exhibitors, staff and the city of Stockholm for making this congress such a big success.

See you in Paris for ESC Congress 2011!

ESC Congress 2010 Hot Line and Clinical Trial Results

View the results of the ESC Congress 2010 Hot Lines and Clinical Trials. Thanks to the generosity of the authors, these results are available in the following formats:

Reports
A selection of slide presentations
A selection of webcasts

View results here

'Continuity' the key for the incoming President of the ESC

Michel Komajda, FESC, has formally taken up the office of ESC President at the ESC Congress 2010 General Assembly.

Prof. Komajda aims to extend the Society’s educational reach with the development of more distance-learning pogrammes, more localised workshops with an emphasis on specialty training, and enhanced platforms involving ESC National Societies for validation and re-validation in cardiology and its sub-specialties...

	Unresolved issues in the surgical treatment of chronic heart failure
	MR has an adverse impact on survival but the question that arises is which patients benefit from sur...

	ESC Congress 2010 awards
	The winners of this year’s Young and Nursing Investigators, Moderated Poster and State of the Art an...

	ESC's new President Elect aims for 'continuation and collaboration'
	The next President of the ESC, Professor Panos E. Vardas from the Heraklion University Hospital and ...

	The evolving story of iron in heart failure
	Cardiologists should recognise the importance of routinely assessing and treating iron deficiency in...

	Clinical Trial Update II: Follow-Up from the International REACH Registry
	Key risk factors for repeat ischaemic events in patients with atherothrombosis have been identified ...

	IV enoxaparin 'more effective' than UFH in reducing PCI complications
	The low molecular weight heparin enoxaparin was more effective in reducing serious ischaemic events ...

	Lessons learnt from stent comparative study
	Everolimus-eluting stents (EES) were associated with lower risks of MI, target vessel revascularisat...

	Congratulations to the winners of the Forum for future leaders in Cardiology
	This Forum included 3 clinical case presentations in three major topics and a panel discussion with ...

	Imaging in stable angina
	Severe stenotic lesions have a higher risk for obstruction, causing an acute coronary syndrome (ACS)...

	Women at Heart Contest: Because women’s hearts are worth it!
	Enter the Women at Heart contest for national societies to raise awareness on women and CVD...

	ESC Congress 2010 Gold Medalists
	Watch the video portrait and discussion with the 2010 Gold Medalists, Prs Christian Cabrol (Paris), ...

	SHIFT: Heart rate in heart failure: risk marker or risk factor? A sub-analysis of the SHIFT trial
	Clinical Trial Update II results: this randomized trial included 6505 patients with...

	Acute and Chronic Heart Failure and Focused Update CRT/HF
	This is the first focused update on the use of CRT and devices in patients with heart failure. T...

	New ESC Guidelines on the Management of Atrial Fibrillation
	New data derived from recent clinical trials have prompted an update of ESC Guidelines on Atrial Fib...

	Hot Line I results: SHIFT
	SHIFT shows that Ivabradine, a selective If inhibitor already investigated for its effects in cor...

	ALPHA OMEGA: Beneficial effect of doses of n-3 fatty acids only in sub-groups of post-MI patients
	Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women followi...

	ICDs for patients with low left-ventricular ejection fraction below 30%
	Professors Maurizio Gasparini and John Cleland debate the impact of implantable cardioverter defibri...

	New ESC Guidelines for Myocardial Revascularisation
	This guideline, jointly developed by the ESC and the European Association for Cardio-Thoracic Sur...

Subscribe for free to the My ESC News, your fortnightly newsletter

ESC RSS Feeds informations

Youtube

Subscribe to the e-Journal of Cardiology Practice

View more events

View more events

	PACE: Pacing to Avoid Cardiac Enlargement (PACE) study
	Yu, Cheuk-Man - Abraham, William

	CARE HF LTFU: Cardiac Resynchronisation in Heart Failure: Long-Term Follow-up
	Cleland, John - Breithardt, Ole A

	TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy
	McMurray, John - Swedberg, Karl

	REALISE-AF registry: an international, observational, cross-sectional survey describing characteristics, cardiovascular risk, and management of patients with atrial fibrillation
	Steg, Philippe Gabriel - Brugada Terradellas, Josep

	KYOTO HEART: Effect of valsartan on cardiovascular outcomes in patients with high-risk hypertension: updated analyses of the KYOTO HEART Study
	Matsubara, Hiroaki - Laurent, Stephane

	JIKEI HEART: Effect of valsartan in Japanese subjects with coronary heart disease: Sub-analysis of results of JIKEI HEART Study
	Shimizu, Mitsuyuki - Maggioni, Aldo Pietro

	DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome
	Nielsen, Jens Cosedis - Blomstrom-Lundqvist, Carina

	RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial
	Peters, Ron J G - Deaton, M Christi

	AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes
	Connolly, Stuart J - Arnesen, Harald

	ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial
	Goette, Andreas - Camm, John

	FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux
	Jolly, Sanjit - Dudek, Dariusz

	INNOVATE PCI: A Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI.
	Rao, Sunil - Kristensen, Steen Dalby

	ART: A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularisation
	Taggart, David - Kappetein, A Pieter

	LESSON I: Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for coronary revascularisation
	Windecker, Stephan - Widimsky, Petr

	ATOLL: An international, randomized trial comparing i.v. enoxaparin with i.v. unfractionated heparin in primary PCI for ST-elevation myocardial infarction
	Montalescot, Gilles - White, Harvey

	ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions
	Schulz, Stefanie - Hamm, Christian

	Double-blind, placebo-controlled phase II studies of E5555 in Japanese patients with Acute Coronary Syndrome (ACS) and Coronary Artery Disease (CAD)
	Goto, Shinya - Van de Werf, Frans

	SHIFT: Heart rate in heart failure: risk marker or risk factor? A sub-analysis of the SHIFT trial
	Böhm, Michael - Kjekshus, John

ESC Congress 2010 top links

	Myocardial revascularisation (ESC/EACTS).
	Philippe H Kolh (BE)

	Discussant: RIKS HIA: Survival benefits by 12 years registry supported improvement of acute cardiac care in the SE – the RIKS-HIA 12 years study
	Susanna Price (UK)

	RIKS HIA: Survival benefits by 12 years registry supported improvement of acute cardiac care in the SE – the RIKS-HIA 12 years study
	Tomas Jernberg (SE)

	Inhibition of tumour angiogenesis and cardiovascular side effects.
	Renu Virmani (US)

	Anti-angiogenesis for wet age-related macular degeneration and diabetic retinopathy.
	Nicolas Leveziel (FR)

	Conventional chemotherapy and cardiac side effects.
	Michael Hallek (DE)

	Galectin-2 expression is dependent on the rs7291467 single nucleotide polymorphism and suppresses collateral artery growth
	Anja van der Laan (NL)

	Proteomic analysis of smooth muscle cells derived from carotid plaque reveals differences between symptomatic & asymptomatic plaques
	Louise Full (UK)

	Hyperosmolarity caused by high levels of glucose and mannitol induces angiogenesis by activating the Tonicity-responsive cis-acting elements, aquaporin 1- and Na+/H+ exchanger 1 and COX-2 and MMPs in human endothelial cells
	Raffaele De Caterina (IT)

	Mitral valve aneurysmal rupture associated with bicuspid aortic valve and aortic valve regurgitation.
	Oya Yuksel (Turkey)

	What do the Guidelines say?
	Raphael Rosenhek (AT)

	A patient with aortic stenosis, aortic regurgitation and mitral regurgitation - Challenges related to disease quantification and surgical indications.
	Pilar Tornos Mas (ES)

	Severe tricuspid regurgitation after mitral valve surgery - which strategy to follow?
	Raphael Rosenhek (AT)

	Discussant: SOURCE REGISTRY TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the source registry
	Gerhard Schuler (DE)

	SOURCE REGISTRY TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the source registry
	Olaf Wendler (UK)

	Discussant: EVOLUTION: Clinical EValuation Of the Edwards Lifesciences percUTaneous mItral annulOplasty system for the treatment of mitral regurgitatioN
	Manuel J Antunes (PT)

	EVOLUTION: Clinical EValuation Of the Edwards Lifesciences percUTaneous mItral annulOplasty system for the treatment of mitral regurgitatioN
	Jan Harnek (SE)

	Neurological problems in patients with endocarditis.
	Jose Alberto San Roman Calvar (ES)

	When to operate and how.
	Manuel J Antunes (PT)

	Prevention and patient education.
	Bernard David Prendergast (UK)

	Transcatheter aortic valve implantation update 2010.
	Thierry Lefevre (FR)

	Low gradient severe aortic stenosis with normal left-ventricular ejection fraction: a disturbing clinical entity.
	Jean-Luc Monin (FR)

	Challenges in assessing aortic stenosis.
	Catherine M Otto (US)

	Prognosis of patients with mild to moderate aortic stenosis.
	Anne Bjorhovde Rossebo (NO)

	Inflammatory imbalance assessed by Fetuin-A and CRP level is a Ssrong predictor of outcome in acute coronary syndromes- from fast-MI registry
	Pascal Lim (FR)

	Repolarisation anomalies and a structurally normal heart.
	Antonio Pelliccia (IT)

	Should all athletes with cardiomyopathy be disqualified from competitive sport?
	Domenico Corrado (IT)

	Acute pulmonary embolism: to thrombolyse or not?
	Adrian Jb Brady (UK)

	Expectations from ongoing trials and new drugs.
	Nazzareno Galie (IT)

	Pharmacological treatment - state of the art.
	Simon Gibbs (UK)

	News on risk stratification.
	Adam Torbicki (PL)

	ESC Guidelines on management of acute pulmonary embolism - is an update needed?
	Arnaud Perrier (CH)

	PEITHO - the hope for 'intermediate-risk' patients.
	Stavros V Konstantinides (GR)

	Largest ever - lessons from RIETE Registry of venous thromboembolism.
	Manuel Monreal Bosch (ES)

	ESC Guidelines versus real-life diagnosis of acute pulmonary embolism - data from ZATPOL Registry.
	Adam Torbicki (PL)

	What is the role of cardiac rehabilitation in addition to optimal treatment?
	Miguel Filipe Mendes (PT)

	What results can be expected from cardiac rehabilitation?
	Neil B Oldridge (US)

	Understanding the mechanisms underlying the benefit.
	Stephan Gielen (DE)

	Triglycerides and cardiovascular risk.
	Marja-Riitta Taskinen (FI)

	High-density lipoprotein and cardiovascular risk.
	John Chapman (FR)

	Cardiovascular benefit of low-density lipoprotein lowering.
	Terje Pedersen (NO)

	Plasma lipid control in Europe: recent data.
	David Allan Wood (UK)

	Global cardiovascular risk: the role of lipids.
	Ian Graham (Ireland)

	Discussant: RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial
	M Christi Deaton (UK)

	RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial
	Ron J G Peters (NL)

	Discussant: ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients
	Luigi Tavazzi (IT)

	Antiplatelet/anticoagulant treatment and risk of bleeding.
	Freek Verheugt (NL)

	Discussant: CURE ACTIVE: Efficacy and Safety of Clopidogrel compared with Placebo according to CYP2C19 Genotype in over 6000 patients with Non-ST-elevation Acute Coronary Syndromes (CURE trial) and atrial fibrillation (ACTIVE trial)
	Robert M Califf (US)

	Stroke and imaging.
	Claudio Rapezzi (IT)

	Discussant: AVERROES (Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes)
	Harald Arnesen (NO)

	AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes
	Stuart J Connolly (CA)

	Positron emission tomography.
	Thomas Hellmut Schindler (CH)

	Single-photon emission computed tomography.
	Marco Mazzanti (IT)

	Cardiovascular magnetic resonance.
	Dudley Pennell (UK)

	Computed tomography and nuclear.
	Philipp A Kaufmann (CH)

	Magnetic resonance imaging.
	Joseph Selvanayagam (AU)

	Echocardiography.
	Nina Ajmone Marsan (NL)

	Cases 2.
	Heikki Ukkonen (FI)

	Cases 1.
	Hans-Marc Siebelink (NL)

	Role of magnetic resonance imaging in the acute myocardial infarction.
	Massimo Lombardi (IT)

	Introduction.
	Steen Dalby Kristensen (DK)

	Discussant: COPPS: COlchicine for the Prevention of the Post-pericardiotomy Syndrome: results of the COPPS trial, a multicentre, double-blind, randomised trial
	Andre Keren (IL)

	COPPS: COlchicine for the Prevention of the Post-pericardiotomy Syndrome: results of the COPPS trial, a multicentre, double-blind, randomised trial
	Massimo Imazio (IT)

	Bacterial infections of the myocardium and pericardium.
	Petar Seferovic (Serbia)

	How to treat viral myocarditis.
	Uwe Kuehl (DE)

	How to diagnose viral infection of the heart and pericardium.
	Sabine Pankuweit (DE)

	Viral myocarditis/pericarditis: pathogenesis.
	Alida Lp Caforio (IT)

	Coronary angiography of pregnancy-associated coronary artery dissection: a high-risk procedure.
	Raphael Pedro Martins (FR)

	What do the Guidelines say?
	Steen Dalby Kristensen (DK)

	NSTEMI - management strategy in a patient with an increased bleeding risk.
	David Erlinge (SE)

	Pretreatment in STEMI.
	Christian Hamm (DE)

	New developments in myocardial perfusion imaging.
	Roxy Senior (UK)

	Cardiovascular genetics and genomics: where will we be in 2015?
	Geoffrey S Ginsburg (US)

	HEBE III: A Single Dose of Erythropoietin in ST-elevation Myocardial Infarction
	Adriaan Voors (NL)

	Haptoglobin deficiency causes cardiac rupture and adverse remodeling after myocardial infarction
	Fatih Arslan (NL)

	Discussant: GRACE: Five year outcomes (UK Belgian collaboration)
	Freek Verheugt (NL)

	GRACE: Five year outcomes (UK Belgian collaboration)
	Keith Fox (UK)

	Discussant: EHS ACS III: Euro Heart Survey Acute Coronary Syndromes III
	Nicolas Danchin (FR)

	EHS ACS III: Euro Heart Survey Acute Coronary Syndromes III
	Francois Schiele (FR)

	Discussant: ACCESS: Acute coronary syndromes (ACS) in Africa, middle-east and latin america: the access registry
	Jose Lopez-Sendon (ES)

	ACCESS: Acute coronary syndromes (ACS) in Africa, middle-east and latin america: the access registry
	Mohamed Sobhy (EG)

	Discussant: REACH Registry: Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or with Atherothrombosis: Final Follow-Up from the International REACH Registry
	Felicita Andreotti (IT)

	REACH Registry: Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or with Atherothrombosis: Final Follow-Up from the International REACH Registry
	Deepak Bhatt (US)

	Discussant: PLATO genetic substrudy: Impact of CYP2C19 and ABCB1 single nucleotide polymorphisms (SNPs) on outcomes with ticagrelor and clopidogrel in acute coronary syndrome - a PLATO genetic substudy
	Kurt Huber (AT)

	PLATO genetic substudy: Impact of CYP2C19 and ABCB1 single nucleotide polymorphisms (SNPs) on outcomes with ticagrelor and clopidogrel in acute coronary syndrome - a PLATO genetic substudy
	Lars Wallentin (SE)

	MULTI STRATEGY: 3-year Follow-up of the Comparison of Angioplasty with Infusion of Tirofiban or Abciximab and with Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction
	Marco Valgimigli (IT)

	Discussant: FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux
	Dariusz Dudek (PL)

	FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux
	Sanjit Jolly (CA)

	Discussant: EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism
	Harald Darius (DE)

	Discussant: Double-blind, placebo-controlled phase II studies of E5555 in Japanese patients with Acute Coronary Syndrome (ACS) and Coronary Artery Disease (CAD)
	Frans Van de Werf (BE)

	Double-blind, placebo-controlled phase II studies of E5555 in Japanese patients with Acute Coronary Syndrome (ACS) and Coronary Artery Disease (CAD)
	Shinya Goto (Japan)

	Discussant: ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions
	Christian Hamm (DE)

	ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions
	Stefanie Schulz (DE)

	Discussant: ATOLL: An international, randomized trial comparing i.v. enoxaparin with i.v. unfractionated heparin in primary PCI for ST-elevation myocardial infarction
	Harvey White (New Zealand)

	Discussant: INNOVATE PCI: A Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI.
	Steen Dalby Kristensen (DK)

	INNOVATE PCI: A Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI.
	Sunil Rao (US)

	Discussant: HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarction
	Piotr Ponikowski (PL)

	HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarction
	Adriaan Voors (NL)

	Percutaneous interventions.
	Nicolas Danchin (FR)

	Fibrinolysis.
	Hector Bueno (ES)

	Prevention.
	Dan Gaita (RO)

	Mechanical support.
	Susanna Price (UK)

	The role of revascularisation.
	Christian Joseph Marie Vrints (BE)

	Pharmacological management.
	Doron Zahger (IL)

	Can interventional cardiologists do better?
	Jens Kastrup (DK)

	Enhanced external counterpulsation.
	Ozlem Soran (US)

	Spinal cord stimulation.
	Mats Borjesson (SE)

	Scale of the problem.
	Anselm Kai Gitt (DE)

	Should we prescribe aspirin and statins to all subjects over 65?
	Terje Pedersen (NO)

	Which stable patient really needs intervention?
	William Boden (US)

	What to do with symptomatic non-obstructive coronary artery disease?
	Raffaele Bugiardini (IT)

	What to do with the 'victims' of non-invasive coronary angiography?
	Attilio Maseri (IT)

	Plaque vulnerability is an important feature of chronic stable coronary disease: a comparison of lesions characteristics in stable angina and acute coronary syndromes from the V-HEART study.
	Nick Palmer (UK)

	Genetic variants related with lipids metabolism genes as a predictor marker of cardiovascular events on stable coronary artery disease.
	Ricardo Vieira (BR)

	Concluding remarks.
	William Wijns (BE)

	New recommendations and open issues.
	Flavio Luciano Ribichini (IT)

	Revascularisation for stable angina.
	David Taggart (UK)

	Revascularisation for acute coronary artery disease.
	Stefan James (SE)

	Decision making, patient information, and risk stratification.
	Volkmar Falk (CH)

	Strength of a joint ESC/EACTS Task Force.
	Philippe H Kolh (BE)

	LESSON I: Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for cOronary revascularisation
	Stephan Windecker (CH)

	Discussant: ISAR TEST 4: Two-year Clinical Outcomes from a Randomized Trial of Biodegradable Polymer Drug-Eluting Stents Versus Permanent Polymer Cypher and Xience Drug-Eluting Stents
	Jean Marco (FR)

	ISAR TEST 4: Two-year Clinical Outcomes from a Randomized Trial of Biodegradable Polymer Drug-Eluting Stents Versus Permanent Polymer Cypher and Xience Drug-Eluting Stents
	Robert Byrne (DE)

	Discussant: Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularisation
	Petr Widimsky (CZ)

	LESSON I: Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for cOronary revascularisation
	Stephan Windecker (CH)

	Contra.
	Marco Roffi (CH)

	Contra.
	Marco Roffi (CH)

	Pro.
	Pim Tonino (NL)

	Contra.
	Marco Valgimigli (IT)

	Pro.
	Thomas Cuisset (FR)

	Contra.
	Marco Valgimigli (IT)

	Pro.
	Thomas Cuisset (FR)

	New drug-eluting stents.
	Alexandre Abizaid (BR)

	Cost-effectiveness.
	David J Cohen (US)

	Optimal antiplatelet therapy.
	Manel Sabate Tenas (ES)

	Current limitations.
	Eric Eeckhout (CH)

	Asian Pacific Society - the view from down under.
	John P Chalmers (AU)

	The view of the British Hypertension Society.
	Adrian Jb Brady (UK)

	Hypertension and peripheral disease.
	Denis Clement (BE)

	What do the Guidelines say?
	Jose Lopez-Sendon (ES)

	Acute heart failure with hypotension and renal dysfunction.
	Alexandre Mebazaa (FR)

	Acutely decompensated chronic ischaemic heart failure with pulmonary congestion.
	Marco Metra (IT)

	2010 focused update of ESC Guidelines on device therapy in heart failure.
	Kenneth Dickstein (NO)

	Heart failure.
	Guillaume Jondeau (FR)

	SHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction
	Michel Komajda (FR)

	Discussant: SHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction
	Inder Anand (US)

	Discussant: PEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to evaluate the effects of RLY5016 in heart failure patients
	Henry J Dargie (UK)

	PEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to evaluate the effects of RLY5016 in heart failure patients
	Bertram Pitt (US)

	Discussant: The STAR Heart Study: the acute and long-term effect of intracoronary stem cell transplantation in 191 patients with chronic heart failure
	Francisco Fernandez-Aviles (ES)

	The STAR Heart Study: the acute and long-term effect of intracoronary stem cell transplantation in 191 patients with chronic heart failure
	Bodo-Eckehard Strauer (DE)

	State of the Art - Paradigm shift in heart failure research - Tribute to Helmut Drexler
	Michael Boehm (DE)

	Diabetes.
	John McMurray (UK)

	Dislipidemia.
	John Kjekshus (NO)

	Hypertension.
	Faiez Zannad (FR)

	Epidemiology of risk factors for coronary artery disease and heart failure.
	Theresa McDonagh (UK)

	Don't know.
	John Cleland (UK)

	Inflammation.
	Gadi Cotter (US)

	Worsening renal function.
	Adriaan Voors (NL)

	Fluid retention.
	Daniela Pini (IT)

	Abnormal haemodynamics.
	Veselin Mitrovic (DE)

	Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure
	Jorgen Amundsen Gravning (NO)

	Circulating microparticles as indicator for vascular damage in peripartum cardiomyopathy
	Katrin Walenta (DE)

	Accelerated progression of stress-induced heart failure in mice with a human CPVT mutation
	Simon Sedej (AT)

	Secretoneurin is a novel peptide increased in the myocardium and circulation in heart failure with cardioprotective properties
	Helge Rosjo (NO)

	Atherosclerosis of the aorta.
	Arturo Evangelista Masip (ES)

	Permanent foramen ovale: when to close?
	Pierre Amarenco (FR)

	The neurologist's point of view.
	Jose Manuel Ferro (PT)

	Endocarditis.
	Gilbert Habib (FR)

	Cardiac sources of embolism.
	Luigi Paolo Badano (IT)

	Valvular regurgitation.
	Maria Joao Andrade (PT)

	Echocardiography.
	Petros Nihoyannopoulos (UK)

	Coronary heart disease.
	Sigmund Silber (DE)

	Transposition of the great arteries with atrial switch versus arterial switch: what do we need to look for and how do we react?
	Folkert Meijboom (NL)

	Tetralogy of Fallot after repair: how to follow and when to re-intervene?
	Philipp Bonhoeffer (UK)

	How to assess and treat obstructive lesions.
	Erwin Oechslin (CA)

	Unoperate shunt lesions in adults: when is closure indicated?
	Helmut Baumgartner (DE)

	Grown-up congenital heart disease.
	Helmut Baumgartner (DE)

	Gene-environment interaction in cardiovascular diseases.
	Harold Snieder (NL)

	Telomerase and Myocardin-A synergistically regulates expression of promyogenic transcription factors in mesenchymal stem cells of adult adipose tissue
	Yong Geng (US)

	“Remote preconditioning reflex” – a neural pathway of cardioprotection during myocardial ischaemia and reperfusion induced by remote ischaemic preconditioning
	Andrey Gourine (UK)

	Prognostic impact of bleeding and transfusion.
	Lucia Torracca (IT)

	Peri-operative pharmacotherapy in high-risk unstable syndromes.
	Jean-Pierre Bassand (FR)

	Ways to improve coronary artery bypass grafting outcomes.
	Volkmar Falk (CH)

	Multivessel and left main disease: indications for surgical and percutaneous intervention.
	William Wijns (BE)

	Discussant: ART: A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularisation
	A Pieter Kappetein (NL)

	ART: A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularisation
	David Taggart (UK)

	Pharmacological postconditioning.
	Michel Ovize (FR)

	Pacing postconditioning.
	Johannes Waltenberger (NL)

	Ischaemic postconditioning.
	Rainer Schulz (DE)

	Preconditioning and its quantitative impact.
	Derek M Yellon (UK)

	Make them play.
	Claudia Walther (DE)

	Childhood obesity; what is the biology and the scale of the problem?
	Paul Leeson (UK)

	How to prevent or reverse ischaemic remodelling: drugs, devices, stem cells?
	Andreas Michael Zeiher (DE)

	Why does a stable patient become unstable?
	Filippo Crea (IT)

	How to reduce residual risk in primary prevention?
	Helene L Glassberg (US)

	Diffuse ST segment elevation and ventricular fibrilation without structural heart disease - a new electrocardiographic presentation of a channelopathy?
	Ana Lebreiro (PT)

	Do not forget the coronary sinus anatomy.
	Christopher Piorkowski (DE)

	Assessing mechanical dyssynchrony: echo is still alive!!!
	Erwan Donal (FR)

	Upstream therapy for primary and secondary prevention.
	Irene Savelieva (UK)

	New indications for new antiarrhythmic drugs?
	Dan Atar (NO)

	Are new guidelines for rate control needed?
	Isabelle C Van Gelder (NL)

	Recommendations and anticipation of new anticoagulation strategies for atrial fibrillation.
	Raffaele De Caterina (IT)

	Atrial fibrillation.
	John Camm (UK)

	Arrhythmia and pacing.
	Panagiotis Vardas (GR)

	EuReCa: monitoring resuscitation practice in Europe.
	Leo L Bossaert (BE)

	Percutaneous coronary intervention after restoration of spontaneous circulation?
	Christian Spaulding (FR)

	Should we use devices for chest compression?
	Sten Rubertsson (SE)

	Therapeutic hypothermia after cardiac arrest.
	Bernd W Boettiger (DE)

	The 2010 evidence-based guidelines: the process, the challenges.
	Jerry Nolan (UK)

	Surgical approach to paroxysmal/persistent atrial fibrillation.
	Ralph J Damiano (US)

	Repeat procedures: the best approach.
	Gerhard Hindricks (DE)

	Patients with persistent/permanent atrial fibrillation.
	Carlo Pappone (IT)

	Patients with paroxysmal atrial fibrillation.
	Eric N Prystowsky (US)

	AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes
	Stuart J Connolly (CA)

	Discussant: ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial
	John Camm (UK)

	ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial
	Andreas Goette (DE)

	Discussant: DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome
	Carina Blomstrom-Lundqvist (SE)

	DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome
	Jens Cosedis Nielsen (DK)

	Falls in the elderly. Diagnostic and therapeutic approach.
	Stylianos Tzeis (GR)

	Syncope in patients without heart disease.
	Angel Moya I Mitjans (ES)

	Syncope evaluation: the role of syncope clinics.
	Michele Brignole (IT)

	An analysis of pathophysiologies.
	Richard Sutton (UK)

	After major bleeding in patients with high risk profile and atrial fibrillation.
	Thomas Meinertz (DE)

	After percutaneous coronary intervention in patients with atrial fibrillation.
	Ariel Cohen (FR)

	Can antithrombotic therapy be withdrawn after successful catheter ablation?
	Claudio Pratola (IT)

	Sporadic or short episodes of paroxysmal atrial fibrillation – still a need for antithrombotic therapy?
	Carina Blomstrom-Lundqvist (SE)

	After successful cardioversion – for how long?
	George K Andrikopoulos (GR)

	In whom and when should atrial fibrillation ablation be considered?
	Christian de Chillou (FR)

	Lessons from recent antithrombotic studies and trials.
	Lars Wallentin (SE)

	Controversies with regard to 'upstream therapy'.
	Barbara Casadei (UK)

	What is the place of old and new antiarrhythmic drugs?
	Isabelle C Van Gelder (NL)

	What is going to be next?
	Christophe Leclercq (FR)

	Don't forget to optimise the device programming.
	Ali Oto (Turkey)

	Is lead placement a real issue?
	Ignacio Fernandez Lozano (ES)

	Don't select the wrong patient.
	Maurizio Gasparini (IT)

	Role of calcineurin/nuclear factor of activated T-cells signalling.
	Ulrich Schotten (NL)

	New mechanistic insights from inherited mutations.
	Ramon Brugada Terradellas (ES)

	Cytoskeleton reorganisation.
	Jan Wilko Schrickel (DE)

	Role of abnormal intracellular calcium release.
	Xander Wehrens (US)

Explore the ESC

ESC Press Office

European Heart House

Connect with the ESC

Find out about ESC Membership

National Societies

Affiliated National Societies

Echocardiography Association (EAE)

Heart Failure Association (HFA)

Heart Rhythm Association (EHRA)

Prevention & Rehabilitation Association (EACPR)

Percutaneous Intervention Association (EAPCI)

ESC Cardiologists of Tomorrow

ESC Working Groups

Find a Cardiology Organisation by Specialty

Educational Courses

ESC Update programmes

ESC Core Curriculum

Online Learning

ESC Congress 2010

Acute Cardiac Care 2010

Heart Failure 2011

EHRA EUROPACE 2011

11th Annual Spring Meeting on Cardiovascular Nursing

EuroPRevent 2011

Frontiers in CardioVascular Biology

World Cardio Agenda

Past Congresses

Guidelines & Surveys

Clinical Practice Guidelines

Guidelines Products

Euro Heart Survey

European Heart Journal

Cardiovascular Research

European Journal of Heart Failure

European Journal of Echocardiography

European Journal of Cardiovascular Nursing

European Journal of Cardiovascular Prevention and Rehabilitation

Subscription Call 2011

Complimentary Journal Subscription

Update your journal information

ESC Journals Corporate Services for Industry

Journal Reviewers: Most Versed In These Matters

European Heart for Children

The European Cookbook

Copyright © European Society of Cardiology 1997 - 2010 - All rights reserved